Peptide Inhibitors of HIV-1 Integrase Useful for the Treatment of Retroviral Infection and HIV
Description of Invention:
The invention describes the discovery of short peptides, derived from the natural peptide named indolicidin that have an ability to inhibit HIV-1 integrase and exhibit antiviral activity. In particular, this invention shows that synthesized derivatives of the indolicidin peptides named RIN-25 exhibit a significant higher anti-viral and anti-integrase activity when compared to the parent compound named RIN-42. HIV-1 integrase has a good potential of being the next therapeutic target since HIV-1 integrase is essential for viral replication and there is no cellular equivalent. Thus, subject invention may be used in the development of therapeutics for the treatment of retroviral infections, such as AIDS, or other retroviral-related diseases (i.e., cancer, immune disorders). In addition, the novel peptides described in this invention may also have particular value when used in combination treatments with other antiviral therapies directed at other viral targets, such as protease and reverse transcriptase.
Inventors:
Peter P. Roller et al. (NCI)
Patent Status:
DHHS Reference No. E-039-2004/0 --
U.S. Provisional Application No. 60/534,378 filed 06 Jan 2004
DHHS Reference No. E-039-2004/1 --
U.S. Provisional Application No. 60/547,067 filed 25 Feb 2004
DHHS Reference No. E-039-2004/2 --
U.S. Provisional Application No. 60/599,856 filed 10 Aug 2004
DHHS Reference No. E-039-2004/3 --
PCT Application No. PCT/US04/42726 filed 21 Dec 2004, which published as WO 2005/068492 on 29 Dec 2005
For Additional Information Please Contact: Sally Hu PhD MBA
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5606
Email: hus@mail.nih.gov
Fax: (301) 402-0220
